Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Rheumatology›Clinical Question·Updated Jul 4, 2026·v1

first-line treatment for acute gout [Grok-4.3]

Colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), oral or intra-articular steroids, or a combination are recommended as first-line pharmacologic therapy for acute gout flares [1]. An interleukin-1 blocker may be considered when colchicine, NSAIDs and corticosteroids are contraindicated [1]. Magnitude of pain reduction was not quantified in

Moderate Evidence22 references·989 words·4 min read·v1
Colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), oral or intra-articular steroids, or a combination are recommended as first-line pharmacologic therapy for acute gout flares [1]. An interleukin-1 blocker may be considered when colchicine, NSAIDs and corticosteroids are contraindicated [1].

Board Review — High Yield

  • •EULAR 2016 recommends colchicine, NSAIDs or corticosteroids (oral/intra-articular) as first-line for acute flares [1]
  • •Traditional limitation of hyperuricemia to gout causation expanded after cohort data linked it to cardiovascular and renal risk, yet randomized trials found no clear outcome benefit from routine urate-lowering in asymptomatic cases [3].
  • •Etanercept 25 mg twice over five days matches methylprednisolone for acute gout flares [9].
  • •Evidence for acute flare options is confined to small open-label studies in refractory cases [9].
  • •Dotinurad 4 mg/day achieved 73.6% responder rate versus 38.1% for febuxostat at week 24 in phase 3 [15].

Deep Dive — Evidence Details

References

  1. [1]

    Richette P, Doherty M, Pascual E et al.. “2016 updated EULAR evidence-based recommendations for the management of gout.” Annals of the rheumatic diseases (2016). PMID: 27457514 ↗

    L2GUIDELINECited in: Bottom Line
  2. [2]

    Sun M, Lyu Z, Wang C et al.. “2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General Patients.” International journal of rheumatic diseases (2025). PMID: 40692263 ↗

    L2GUIDELINECited in: Bottom Line
  3. [3]

    Johnson R, Gruev I, Yotov Y et al.. “Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2025 update.” European journal of internal medicine (2026). PMID: 41786537 ↗

    L2GUIDELINECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  4. [4]

    Li T, Lu Z, Peng W et al.. “Oatmeal-based fiber diet outperforms resistant starch-based fiber diet in lowering serum uric acid via gut microbiota-metabolite interactions: a randomized controlled trial.” Food & function (2026). PMID: 42171138 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  5. [5]

    Liu Y, Hua C, Wu Y et al.. “Evaluation of the clinical efficacy of Xanthoceras sorbifolium leaves in intervening in hyperuricemia and research on its uric acid-lowering mechanism.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 42160899 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  6. [6]

    Moses A, Oude Voshaar MAH, van Geel EH et al.. “A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial.” The Lancet. Rheumatology (2026). PMID: 41865749 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  7. [7]

    Sakaguchi T, Arima H, Okada M et al.. “Efficacy and safety of low-dose combination urate-lowering agent therapy versus standard-dose monotherapy in patients with hyperuricemia and/or gout: a systematic review and meta-analysis of randomized controlled trials.” BMC nephrology (2026). PMID: 42277723 ↗

    L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  8. [8]

    Zhang Z, Feng Z, Yan W et al.. “Tart cherry intake and serum uric acid: Meta-analysis of randomized controlled trials and evidence from network pharmacology.” Asia Pacific journal of clinical nutrition (2026). PMID: 42242852 ↗

    L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  9. [9]

    Luo J, Xie Z, Zhang W et al.. “Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein as Treatment for Gout Flare.” International journal of rheumatic diseases (2026). PMID: 41949339 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  10. [10]

    Jiang S, Lin L, Duan X et al.. “Indobufen versus aspirin in dual antiplatelet therapy: a retrospective study of effects on serum uric acid levels and gout attacks in patients post-coronary stenting.” PeerJ (2026). PMID: 41918864 ↗

    L3COHORTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  11. [11]

    Wang N, Li M, Lu M et al.. “Therapeutic effects and mechanisms of Artemisia species on metabolic diseases: A systematic review.” Medicine (2026). PMID: 42332507 ↗

    L2SR_OBSCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  12. [12]

    Wang YC, Huang AP, Huang CW et al.. “Association Between Gout and the Risk of Dementia: A Meta-Analysis of Observational Studies and Biological Mechanisms.” International journal of rheumatic diseases (2026). PMID: 41782208 ↗

    L2SR_OBSCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  13. [13]

    Tan J, Huang H, Tan L et al.. “Firsekibart for steroid withdrawal in glucocorticoid-dependent refractory gout: a case report.” Frontiers in immunology (2026). PMID: 41953015 ↗

    L4CASE_REPORTCited in: Current Evidence and Standard
  14. [14]

    Eliseev MS, Chikina MN, Kuzmina YI et al.. “Efficacy and Safety of Long-term Administration of Various Doses of Colchicine in Patients with Gout.” Doklady. Biochemistry and biophysics (2026). PMID: 41912854 ↗

    L1RCTCited in: Current Evidence and Standard
  15. [15]

    Sun J, Wang Y, Cheng Y et al.. “Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40417858 ↗

    L1RCTCited in: On the Horizon
  16. [16]

    Ghang B, Park J, Lee JS et al.. “Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy.” Kidney international (2024). PMID: 39551133 ↗

    L1RCTCited in: On the Horizon
  17. [17]

    Doehner W, Anker SD, Butler J et al.. “Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial.” JACC. Heart failure (2024). PMID: 39453357 ↗

    L1RCTCited in: On the Horizon
  18. [18]

    Tabi-Amponsah AD, Doherty M, Sarmanova A et al.. “Post-hoc analysis of two gout remission definitions in a two-year randomized controlled trial of nurse-led versus usual gout care.” Seminars in arthritis and rheumatism (2024). PMID: 39326192 ↗

    L1RCTCited in: On the Horizon
  19. [19]

    Luo Y, Jiang H, Shi B et al.. “Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.” Contemporary clinical trials (2025). PMID: 41260459 ↗

    L2TRIAL_NONRANDOMCited in: On the Horizon
  20. [20]

    Saag KG, Dalbeth N, Hsu CY et al.. “Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies.” Contemporary clinical trials (2025). PMID: 39929260 ↗

    L2TRIAL_NONRANDOMCited in: On the Horizon
  21. [21]

    Liu J, Gamble GD, Dalbeth N. “Are participants in gout medication registration clinical trials representative of people with gout in the general population?” Seminars in arthritis and rheumatism (2025). PMID: 39919487 ↗

    L2TRIAL_NONRANDOMCited in: On the Horizon
  22. [22]

    Troum OM, Duong M, Obermeyer K et al.. “Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase.” Rheumatology (Oxford, England) (2025). PMID: 39792028 ↗

    L2TRIAL_NONRANDOMCited in: On the Horizon

Revision History

All updates applied to this page

Loading revisions…